Third Harmonic Bio, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on the development of medicine for the treatment of allergic and inflammatory diseases. Third Harmonic Bio serves customers in the United States.

Current Report (Form 8-K | Period ending 2024-11-07)

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Third Harmonic Bio (THRD US)

Current Report (Form 8-K | Period ending 2024-11-07)

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Current Report (Form 8-K | Period ending 2024-08-08)

Quarterly Report (Form 10-Q | Period ending 2024-06-30)

Current Report (Form 8-K | Period ending 2024-06-06)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)